To evaluate the hemodynamic changes occurring after rescue surfactant dosing in relation to the clinical respiratory response in preterm infants with respiratory distress syndrome. STUDY DESIGN: We studied 20 infants who received surfactant (poractant alfa) after failing continuous positive airway pressure (CPAP) beyond 2 h of life. Consecutive echocardiograms were performed before the surfactant dose, 10 min after and 1 h after the surfactant dose. Superior vena cava flow, right ventricular output, atrial and patent ductus arteriosus diameter and direction of shunting were measured. A surfactant responder (SR) was defined as an infant whose inspired fraction of oxygen was reduced to air (0.21) by 3 h after surfactant administration. A surfactant non-responder (SNR) was defined as an infant who remained on more than 0.21 at 3 h postsurfactant administration. Concurrent physiological parameters (heart rate, transcutaneous CO 2 , mean arterial blood pressure, mean airway pressure) were also recorded. Subject characteristics were compared relative to noted hemodynamic effects. RESULT: Of the 20 infants enrolled in the study, 12 were SR. These infants received surfactant earlier and had increased measures of systemic blood flow after receipt of surfactant compared with baseline. SNR did not have changes in systemic blood flow from baseline after surfactant dosing. There was no change in ductal shunting or atrial shunting between the two groups. CONCLUSION: A good clinical response to rescue surfactant is seen in infants who received surfactant earlier and is associated with increase in systemic blood flow. Timing of rescue surfactant administration needs to be further evaluated in larger prospective studies.
INTRODUCTION
In the modern era of neonatal intensive care, surfactant has dramatically improved survival of infants with respiratory distress syndrome. In the years before widespread use of antenatal steroids, surfactant therapy compared with ventilation alone in preterm infants was proven to decrease mortality and air leaks. 1 Recent large multicenter trials have reported similar rates of survival without BPD in infants o29 weeks gestation treated with early surfactant or early continuous positive airway pressure (CPAP) with rescue surfactant therapy. [2] [3] [4] Practice for many centers has changed to early use of CPAP with rescue surfactant administration. However, surfactant administration can have a number of potential problems. In some infants surfactant may not distribute rapidly leading to obstruction and or the need for excessive ventilation for a period of time. Some studies have demonstrated brain activity suppression, 5 increases in the indomethacin doses needed for patent ductus arteriosus (PDA) treatment 6 and pulmonary hemorrhage. 7 Some of these changes may be related to an alteration in hemodynamics that occurs with surfactant administration.
Studies evaluating hemodynamic changes with surfactant administration have had variable findings with some showing increases in cerebral blood flow 8, 9 and others demonstrating decreases in cerebral blood flow 10 and pulmonary artery pressure. 11, 12 Still, others report no changes in pulmonary artery pressure or pulmonary blood flow despite an improvement in oxygenation. [13] [14] [15] Differences in timing of administration of surfactant therapy, exposure to antenatal steroids and type of surfactant preparation may contribute to disparate findings. Clinical observations suggest that some infants do not tolerate the dose of surfactant well. The objective of our study was to determine whether infants with different respiratory responses to surfactant also have different hemodynamic responses to surfactant.
METHODS

Study design
We conducted a prospective observational study in our neonatal intensive care unit (NICU) at the University of California San Diego (UCSD) Medical Center evaluating the hemodynamic effects of rescue surfactant (given after 2 h of life).
Pregnant women were approached antenatally from the UCSD labor and delivery service or postpartum if their infant was admitted to the NICU for respiratory distress. Infants were excluded if they did not require surfactant during their hospitalization, received surfactant in the delivery room, had known chromosomal anomalies, or if the investigator was unavailable to perform the echocardiograms. All infants had a full screening echocardiogram to exclude congenital heart defects.
Patients were enrolled from December 2009 through January 2011. The study sample consisted of 20 infants who were admitted to our NICU and received surfactant replacement therapy as determined by the clinical team. All subjects had significant respiratory distress and/or required greater than 30% oxygen therapy on CPAP. All study participants received poractant alpha (Curosurf, Dey LP, Napa, CA USA and Chiesi Farmaceutici Spa Parma, Italy). The institutional review board of the UCSD approved the study and signed informed consent was obtained from parents or legal guardians before enrollment.
Study protocol
Echocardiograms were performed immediately before the surfactant dose, 10 min after surfactant administration, and at 1 h after surfactant administration. Echocardiograms were performed using the Vivid i cardiovascular ultrasound system (GE Medical Systems, Milwaukee, WI, USA) with either the 7S or 10S phased array transducer probe. Echocardiograms were performed and measured by the principal investigator (AK) at the time of each study and images were reviewed by the second investigator (TL) to confirm the quality of the studies. Measures of superior vena cava (SVC) flow, right ventricular output (RVO), diameter of the PDA and flow through the foramen ovale were obtained. In addition, direction of blood flow at the PDA and at the foramen ovale were documented on each exam.
All flow measures were calculated and indexed to weight by determining the cross sectional area from the measured diameter of the blood vessel, the velocity time integral from the pulse wave Doppler signal, and heart rate using the formula: Cross Sectional Area Â Velocity Time Integral (velocity time integral) Â Heart Rate/Weight (kg).
The RVO was measured by obtaining the vessel diameter and the velocity from the parasternal long axis window in the sagittal plane. The Doppler range gate was placed in the middle of the pulmonary artery distal to the pulmonary valve. The diameter was measured at the level of the pulmonic valve from images of three cardiac cycles and values were averaged. The velocity time integral from five consecutive cardiac cycles and values were averaged.
The SVC flow was measured by obtaining the vessel diameter from the parasternal long axis window in a sagittal plane and the velocity time integral from the subcostal window. The doppler range gate was placed at the junction of the SVC and the right atrium. The average of the maximum and minimum diameter from three cardiac cycles was calculated. The velocity time integral from 10 consecutive cardiac cycles were obtained and values were averaged.
The ductus arteriosus was imaged from the high-parasternal window with the transducer angled to obtain a view of the ductus throughout its course from the pulmonary artery to the descending aorta. The direction of flow was assessed by placing the pulse wave doppler range gate in the center of the ductus and recording the flow pattern. The direction of flow was categorized as all left to right, all right to left or bidirectional. If bidirectional, the percentage of right to left flow was calculated by measurement of the time of right to left component over the time of the entire cardiac cycle.
Atrial shunting was imaged from the subcostal window and determined by measuring the diameter of the color flow jet across the atria. The color scale was lowered until atrial flow was seen and the gain was adjusted until the color signal was optimized. The pulsed wave doppler range gate was placed in the foramen ovale and the pattern of flow was classified as left to right or bidirectional.
Data collection
Relevant prenatal and neonatal data were obtained from the medical record. The clinical respiratory response to surfactant was evaluated and subjects were categorized as surfactant responders (SR) or surfactant non-responders (SNR). Subjects were categorized as SR if the inspired fractional oxygen concentration (FiO 2 ) was 0.21 by 3 h postsurfactant administration. Subjects were categorized as SNR if the FiO 2 was40.21 at 3 h after the surfactant dose. The FiO 2 was decreased per the practice in our unit at that time to keep postductal saturations 88 to 92% for preterm infants. Results were recorded from neuroimaging studies performed per our routine practice for premature infants.
Data analysis
As there were no preliminary data regarding measures of systemic blood flow (RVO and SVC flow) before and after rescue surfactant we chose a sample size of 20 patients to perform this pilot study. Statistics were performed using PASW Statistics 18.0 (Chicago, IL, USA). Descriptive statistics were used to characterize baseline neonatal demographics and echocardiographic measures. Repeated measure analysis (analysis of variance) was used to analyze serial changes over time in measures of systemic blood flow (SVC flow, RVO), atrial shunting, blood pressure and heart rate. The subjects' characteristics and outcomes were compared using Student's t-test for parametric continuous variables and Mann À Whitney U test for nonparamentric continuous variables, and w 2 for categorical variables. Paired sample t-tests were also used to compare differences between repeat echocardiographic measures within each subject. Two sided P valueo0.05 were considered significant.
RESULTS
Twenty-five infants were consented for the study, of which 20 were intubated for surfactant replacement therapy after failing early CPAP. Twelve infants in the study were in the SR group. SR received surfactant earlier (Table 1 ) compared with NSR. SR also had increases in systemic blood flow (RVO and SVC flow) after surfactant treatment compared with baseline (Table 2 ). There were no significant changes in the diameter or percentage of right to left shunting of the PDA or in the atrial shunt between the two groups. None of the infants had intraventricular or intracranial hemorrhage at baseline. One infant in each group (SR and NSR) developed a subependymal hemorrhage (Grade 1) between 48 and 72 h of life. One infant (in the NSR group) had very low SVC flows and RVO at 10 min and 1 h after surfactant dosing (SVC: 47 and 39 ml kg À 1 min À 1 , RVO: 99 and 43 ml kg À 1 min À 1 respectively), and developed pulmonary hemorrhage and grade 4 intracerebral hemorrhage (IVH) at 24 h of life. This infant initially had a normal head ultrasound at 6 h of life but at 24 h of life developed significant bilateral IVH.
DISCUSSION
Our study is the first to examine measures of systemic blood flow in neonates receiving rescue surfactant therapy after early CPAP.
We were able to demonstrate that improvements in oxygenation after receipt of surfactant are associated with an improvement in systemic blood flow. We also demonstrated that infants who received rescue surfactant earlier are more likely to respond to surfactant.
A recent single center study of 16 infantso32 weeks gestation who received early surfactant (mean 21 ± 2 min) demonstrated an increase in the PDA diameter and RVO with a decrease in left ventricular output at 30 and 60 min postsurfactant. 16 Interestingly the values of SVC flow and RVO were much lower than levels reported by other groups. 17 There were three infants with IVH, all of whom survived. The impact of low flow this early after birth is unknown. Low SVC flow in infantso30 weeks, measured at 3 to 5 h of life and throughout the first 48 h of life, is associated with severe intracranial hemorrhage and poor neurodevelopmental outcome at 3 years of age. 18, 19 Our study cohort was more mature (average gestation 31 weeks) and had hemodynamic measurements much later (average time 13 h in the SNR group).
One study of ventilated preterm infants looked at the severity of respiratory disease (determined by the mean FiO 2 over the first 24 h) and ventricular outputs and found that a lower RVO correlated with the severity of respiratory disease. 20 In our study infants in the SNR group tended to have a higher FiO 2 at the time of surfactant administration. This suggests that delaying surfactant to a point when respiratory distress syndrome is more severe may lead to significant hemodynamic compromise. In our study, we did not frequently see levels of systemic blood flow low enough to be associated neurologic injury. This is likely due to the relatively mature gestational age of our study population.
The one infant in our study that did develop a severe IVH had normal measures of systemic blood flow before surfactant administration but then fell to very low levels at 10 min and 1 h after receiving surfactant. This infant also had a doubling of ductal diameter within 1 h of receipt of surfactant. Despite initially having normal head US and blood pressures, the infant went on to develop severe hypotension, pulmonary hemorrhage and IVH. Surfactant therapy may cause pulmonary hemorrhage by inducing a rapid lowering of intrapulmonary pressure, which facilitates leftto-right shunting across a patent ductus arteroisus and an increase in pulmonary blood flow. 21 A recent abstract suggested that early closure of the PDA (3 h to 12 h) by indomethacin reduces the incidence of pulmonary hemorrhage in infantso30 weeks of age. 22 Although our study did not detect difference in the change in PDA size in the infants who received surfactant, our study was underpowered to detect a difference.
There are a number of limitations to our study such as our small sample size, which may have limited our ability to detect other inter-group differences. Our subjects were also likely to be more stable as they were required to have been on nasal CPAP for at least 2 h prior to enrollment. Although no statistically significant infants who were responders were more mature which could have confounded our results. We also did not include a control group of infants who did not receive surfactant. Therefore our results are only generalizable to infants who had delayed surfactant administration for respiratory distress syndrome. There are also limitations of our echocardiography analysis. We did not perform a comprehensive evaluation of hemodynamics due to time constraints as we intended to minimize handling during and after the administration of surfactant. The measures we chose were those that were most specific for systemic blood flow during the transitional period.
The ability to measure real-time blood flow changes at the bedside can have many potential advantages. We were able to detect changes in systemic blood flow within 10 min of receipt of surfactant, well before the FiO 2 was decreased. Clinician performed ultrasound in the NICU has become more prevalent in other countries, 23 and can be especially helpful in management of newborns in the early transitional period. This study suggests that clinicians should consider a more thorough hemodynamic evaluation of infants who do not have a good clinical response to surfactant. Further studies of the hemodynamics associated with surfactant administration in more immature infants may be helpful in determining the most appropriate timing of surfactant dosing.
In conclusion a good clinical response to rescue surfactant is associated with increases in systemic blood flow. Administration of rescue surfactant early in the disease process may improve the hemodynamic response to surfactant, but this needs further prospective evaluation. 2.1 ± 0.5 2.1 ± 0.6 1.9 ± 0.7 0.412 1.9 ± 0.6 2.2 ± 0.9 2 ± 0. 
